PDCD1 and myelodysplastic syndrome: The overall response rate was significantly lower (8% vs. 60%, p = 0.014), and a trend towards a shorter overall survival (p = 0.11) was observed in MDS/AML patients, in whom the demethylation of the PD-1 promoter occurred [48].